420 related articles for article (PubMed ID: 28105738)
1. Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes.
Storgaard H; Cold F; Gluud LL; Vilsbøll T; Knop FK
Diabetes Obes Metab; 2017 Jun; 19(6):906-908. PubMed ID: 28105738
[TBL] [Abstract][Full Text] [Related]
2. Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials.
Monami M; Dicembrini I; Nardini C; Fiordelli I; Mannucci E
Diabetes Res Clin Pract; 2014 Feb; 103(2):269-75. PubMed ID: 24485345
[TBL] [Abstract][Full Text] [Related]
3. Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials.
Monami M; Nreu B; Scatena A; Cresci B; Andreozzi F; Sesti G; Mannucci E
Diabetes Obes Metab; 2017 Sep; 19(9):1233-1241. PubMed ID: 28244632
[TBL] [Abstract][Full Text] [Related]
4. Tumour Risk with Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus Patients: A Systematic Review.
Guo X; Yang Q; Dong J; Liao L; Zhang W; Liu F
Clin Drug Investig; 2016 Jun; 36(6):433-41. PubMed ID: 26979594
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular safety and benefits of GLP-1 receptor agonists.
Dalsgaard NB; Brønden A; Vilsbøll T; Knop FK
Expert Opin Drug Saf; 2017 Mar; 16(3):351-363. PubMed ID: 28102093
[TBL] [Abstract][Full Text] [Related]
6. [Impact of glucagon-like peptide-1 receptor agonists on nasopharyngitis and upper respiratory tract infection among patients with type 2 diabetes: a network meta-analysis].
Li ZX; Wu SS; Yang ZR; Zhan SY; Sun F
Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Jun; 48(3):454-9. PubMed ID: 27318907
[TBL] [Abstract][Full Text] [Related]
7. Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies.
Li L; Li S; Liu J; Deng K; Busse JW; Vandvik PO; Wong E; Sohani ZN; Bala MM; Rios LP; Malaga G; Ebrahim S; Shen J; Zhang L; Zhao P; Chen Q; Wang Y; Guyatt GH; Sun X
BMC Cardiovasc Disord; 2016 May; 16():91. PubMed ID: 27169565
[TBL] [Abstract][Full Text] [Related]
8. Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis.
Sun F; Wu S; Guo S; Yu K; Yang Z; Li L; Zhang Y; Quan X; Ji L; Zhan S
Diabetes Res Clin Pract; 2015 Oct; 110(1):26-37. PubMed ID: 26358202
[TBL] [Abstract][Full Text] [Related]
9. Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials.
Dicembrini I; Nreu B; Scatena A; Andreozzi F; Sesti G; Mannucci E; Monami M
Acta Diabetol; 2017 Oct; 54(10):933-941. PubMed ID: 28748377
[TBL] [Abstract][Full Text] [Related]
10. Do GLP-1 Receptor Agonists Increase the Risk of Breast Cancer? A Systematic Review and Meta-analysis.
Piccoli GF; Mesquita LA; Stein C; Aziz M; Zoldan M; Degobi NAH; Spiazzi BF; Lopes Junior GL; Colpani V; Gerchman F
J Clin Endocrinol Metab; 2021 Mar; 106(3):912-921. PubMed ID: 33248445
[TBL] [Abstract][Full Text] [Related]
11. Risk of acute pancreatitis with incretin-based therapy: a systematic review and updated meta-analysis of cardiovascular outcomes trials.
Singh AK; Gangopadhyay KK; Singh R
Expert Rev Clin Pharmacol; 2020 Apr; 13(4):461-468. PubMed ID: 32129106
[TBL] [Abstract][Full Text] [Related]
12. Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide.
Nauck MA; Frossard JL; Barkin JS; Anglin G; Hensley IE; Harper KD; Milicevic Z
Diabetes Care; 2017 May; 40(5):647-654. PubMed ID: 28283565
[TBL] [Abstract][Full Text] [Related]
13. Treatment Strategy for Type 2 Diabetes with Obesity: Focus on Glucagon-like Peptide-1 Receptor Agonists.
Ji Q
Clin Ther; 2017 Jun; 39(6):1244-1264. PubMed ID: 28526416
[TBL] [Abstract][Full Text] [Related]
14. Effects of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) on Cardiac Structure and Function: A Systematic Review and Meta-Analysis of Randomized-Controlled Trials.
Wong SY; Lee ARYB; Sia AHJ; Wo YJ; Teo YH; Teo YN; Syn NL; Ong CC; Teo LL; Yeo TC; Poh KK; Kong WK; Wong RC; Sia CH
Cardiovasc Drugs Ther; 2024 Apr; 38(2):371-389. PubMed ID: 35819544
[TBL] [Abstract][Full Text] [Related]
15. GLP-1 receptor agonists and pancreatic safety concerns in type 2 diabetic patients: data from cardiovascular outcome trials.
Cao C; Yang S; Zhou Z
Endocrine; 2020 Jun; 68(3):518-525. PubMed ID: 32103407
[TBL] [Abstract][Full Text] [Related]
16. No pancreatic safety concern following glucagon-like peptide-1 receptor agonist therapies: A pooled analysis of cardiovascular outcome trials.
Liu Y; Tian Q; Yang J; Wang H; Hong T
Diabetes Metab Res Rev; 2018 Nov; 34(8):e3061. PubMed ID: 30109766
[TBL] [Abstract][Full Text] [Related]
17. Glucagon-Like Peptide-1 Receptor Agonist and Risk of Diabetic Retinopathy in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Placebo-Controlled Trials.
Jiao X; Peng P; Zhang Q; Shen Y
Clin Drug Investig; 2023 Dec; 43(12):915-926. PubMed ID: 37938535
[TBL] [Abstract][Full Text] [Related]
18. The Role of the Pharmacist in Managing Type 2 Diabetes with Glucagon-Like Peptide-1 Receptor Agonists as Add-On Therapy.
Meece J
Adv Ther; 2017 Mar; 34(3):638-657. PubMed ID: 28210986
[TBL] [Abstract][Full Text] [Related]
19. Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes.
Lovshin JA
Can J Diabetes; 2017 Oct; 41(5):524-535. PubMed ID: 28942790
[TBL] [Abstract][Full Text] [Related]
20. Pancreatitis and pancreatic cancer in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists: an updated meta-analysis of randomized controlled trials.
Nreu B; Dicembrini I; Tinti F; Mannucci E; Monami M
Minerva Endocrinol (Torino); 2023 Jun; 48(2):206-213. PubMed ID: 32720500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
